Skip to main content

Advertisement

Table 4 Mean urinary (±SD) concentrations and clinical associations of 10 biomarkers in cohort #2 assessed by Multi-Array assay

From: A multiplex immunoassay for the non-invasive detection of bladder cancer

  Total bladder cancer (50 %), n = 100 Low-grade bladder cancer (21 %), n = 21 High-grade bladder cancer (79 %), n = 79 NMIBC (58 %), n = 58 MIBC (42 %), n = 42 Total controls (50 %), n = 100
IL8 (pg/ml)*, ^, + 761.6 ± 804.4 348.3 ± 541.8 871.5 ± 829.4 593.2 ± 766.8 994.3 ± 805.9 122.8 ± 380.1
MMP9 (ng/ml)*, + 115.7 ± 392.9 26.0 ± 61.0 139.6 ± 438.4 89.0 ± 362.1 152.6 ± 433.6 2.8 ± 11.7
A1AT (ng/ml)*, + 4002.6 ± 7384.7 2961.5 ± 7204.7 4279.4 ± 7452.3 3949.8 ± 8302.9 4075.6 ± 5985.6 993.6 ± 2962.6
ANG (pg/ml)*, + 6501.0 ± 23,967.9 10,109.0 ± 42,456.3 5541.9 ± 16,201.7 6567.1 ± 27,404.6 6409.7 ± 18,520.3 619.0 ± 1093.1
VEGFA (pg/ml)*, + 1321.0 ± 1969.9 971.0 ± 1747.0 1414.1 ± 2025.0 1082.0 ± 1832.9 1651.1 ± 2122.9 570.4 ± 586.8
CA9 (pg/ml)* 168.6 ± 461.9 126.9 ± 398.6 179.7 ± 479.0 142.9 ± 409.9 204.1 ± 528.6 1.0 ± 0.0
MMP10 (pg/ml)*, ^, + 2576.3 ± 12,512.1 977.4 ± 3490.8 3001.3 ± 13,953.7 1444.5 ± 5444.0 4139.2 ± 18,234.5 5.0 ± 0.0
APOE (pg/ml)* 199,003.5 ± 587,474.7 202,108.4 ± 695,029.2 198,178.2 ± 560,516.7 266,463.1 ± 751,668.8 105,845.1 ± 180,362.0 21,654.7 ± 37,121.9
PAI1 (ng/ml)*, ^, + 26.2 ± 53.7 12.4 ± 43.8 29.9 ± 55.7 17.6 ± 47.8 38.1 ± 59.5 0.7 ± 3.8
SDC1 (pg/ml) 14,853.3 ± 43,824.9 9958.5 ± 9625.1 16,154.4 ± 49,048.9 10,814.6 ± 15,586.0 20,430.5 ± 65,153.2 10,459.7 ± 14,248.5
  1. NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer
  2. P < 0.05 comparing total bladder cancer to total controls
  3. ^ P < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer
  4. + P < 0.05 comparing NMIBC to MIBC